Lung cancer is one of the most common cancer in the world. In 2018, there were over 2
million new cases of lung cancer and over 1.7 million deaths were attributed to lung cancer …

Lung cancer is currently the second most common type of cancer with the second incidence
rate and the first mortality rate worldwide. Non-small cell lung cancer (NSCLC) accounts for …

Sodium taurocholate cotransporting polypeptide (NTCP) is a host cell receptor required for
hepatitis B virus (HBV) entry. However, the susceptibility of NTCP-expressing cells to HBV is …

The over expression of EGFR has been recognized as the driver mechanism in the
occurrence and progression of carcinomas such as lung cancer, breast cancer, pancreatic …

Nanobodies are antibody fragments derived from camelids, naturally endowed with
properties like low molecular weight, high affinity and low immunogenicity, which contribute …

Reactive oxygen species (ROS) are physiological mediators of cellular signaling and play
potentially damaging roles in human diseases. In this study, we found that the catalytic …

Tyrosine kinase inhibitors (TKIs) that target epidermal growth factor receptor (EGFR) have
dramatically improved progression-free survival in non-small-cell lung cancer (NSCLC) …

Epidermal growth factor receptor (EGFR), also known as ErbB-1/HER-1, plays a key role in
the regulation of the cell proliferation, migration, differentiation, and survival. Since the …

Epidermal growth factor receptor (EGFR) mutation is the most common driver mutation in
non-small cell lung cancer (NSCLC). The first-line therapy for advanced NSCLC patients …

Lung cancer is one of the most common and deadly types of cancer worldwide, and the
epidermal growth factor receptor (EGFR) has emerged as a promising therapeutic target for …